首页> 外文期刊>Research and practice in thrombosis and haemostasis. >External qualification of the Web-Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data
【24h】

External qualification of the Web-Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data

机译:使用真实患者数据的网页可访问人口药代动力学服务 - 血友病(WAPPS-HEMO)模型的外部资格

获取原文
           

摘要

Background Existing adult patient pharmacokinetic (PK) data from the published Advate vs Kovaltry PK crossover study were used for this validation study. This data set is appropriate for qualification, given that it has not been previously submitted to Web-Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS-Hemo) and will not have impacted the WAPPS-Hemo models for Kovaltry. Objective To compare the population PK parameters for Kovaltry (BAY 81-8973) derived from the WAPPS-Hemo models with PK parameters derived from noncompartmental analysis (NCA), using a validation PK dataset. Methods The qualification data set included Kovaltry factor activity (10?samples per infusion) and anthropometric data for 18 patients. Two analyses were performed comparison of Bayesian forecasting from the WAPPS-Hemo models versus NCA using the full 10-sample data set; and comparison of Bayesian forecasting using the full versus reduced 4- and 3-sample data sets. Agreement between outcomes was assessed by quantifying the variability and bias of the error. Results Comparison of WAPPS-Hemo models versus NCA led to well-correlated outcomes despite a systematic overprediction of clearance. Population PK models demonstrated greater consistency with NCA on one-stage data, compared with chromogenic data. WAPPS-Hemo model results were consistent in reduced sampling compared to full sampling. Inclusion of a 48-hour time point in the reduced sampling greatly improved the consistency with full sampling. Discussion Qualification of population PK models and their use for Bayesian forecasting in full and reduced sampling is an essential step toward their validation. The evaluations performed in this study support the confidence of PK parameter estimates provided by the models.
机译:背景技术来自已发表的提出的ADVATE VS KOValtry PK交叉研究的现有成年患者药代动力学(PK)数据用于该验证研究。本数据集适用于资格,鉴于以前未提交给网络可访问的人口药代动力学服务 - 血友病(WAPPS-HEMO),并且不会影响Kovaltry的WAPPS-HEMO模型。目的使用验证PK数据集比较从WAPPS-HEMO模型衍生自WAPPS-HEMO模型的Kovaltry(湾81-8973)的人口PK参数。方法对18名患者的鉴定数据集包括Kovaltry因子活性(10?每次输注的样品)和人体测量数据。使用完整的10样本数据集进行了两次分析对WAPPS-HEMO模型与NCA的比较;并使用完整的贝叶斯预测的比较减少4-和3样本数据集。通过量化误差的可变性和偏差来评估结果之间的协议。结果比较WAPPS-HEMO模型与NCA的比较导致了良好的差异良好的清除。与发色数据相比,人口PK模型在一级数据上表现出更大的一致性。与全抽样相比,WAPPS-HEMO模型结果在减少的采样中一致。在减少的采样中包含48小时的时间点大大提高了完全取样的一致性。讨论人口PK模型的资格及其对贝叶斯预测的充分和减少抽样的用途是朝着他们验证的重要一步。本研究中进行的评估支持模型提供的PK参数估计的置信度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号